<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Minocycline</strong></td></tr><tr><th>Accession Number</th><td><strong>DB01017</strong>&#160; (APRD00547)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>A tetracycline analog, having a 7-dimethylamino and lacking the 5 methyl and hydroxyl groups, which is effective against tetracycline-resistant staphylococcus infections. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB01017/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB01017/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01017.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01017.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01017.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01017.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01017.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB01017">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>7-Dimethylamino-6-demethyl-6-deoxytetracycline</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Minociclina</td><td>Spanish</td><td>INN</td></tr><tr><td>Minocyclin</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Minocyclinum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Minocycline Hydrochloride</strong>
          <div class="cas">13614-98-7</div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000721/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000721/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: WTJXVDPDEQKTCV-VQAITOIOSA-N</li>
              <li>Monoisotopic Mass: 493.161577972</li>
              <li>Average Mass: 493.937</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000721">DBSALT000721</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Aknemin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Apo-Minocycline</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Arestin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Dynacin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Klinomycin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Minocin</td><td>Triax Pharmaceuticals, LLC]</td></tr><tr><td>Minoderm</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Minomycin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Minopen</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Minox</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Minoz</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Solodyn</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Vectrin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Ximino</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/anti-bacterial-agents">Anti-Bacterial Agents</a></li>
<li><a href="/mesh/tetracyclines">Tetracyclines</a></li></ul></td></tr><tr><th>CAS number</th><td>10118-90-8</td></tr><tr><th>Weight</th><td>Average: 457.4764<br>Monoisotopic: 457.184900233</td></tr><tr><th>Chemical Formula</th><td>C<sub>23</sub>H<sub>27</sub>N<sub>3</sub>O<sub>7</sub></td></tr><tr><th>InChI Key</th><td>DYKFCLLONBREIL-KVUCHLLUSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C23H27N3O7/c1-25(2)12-5-6-13(27)15-10(12)7-9-8-11-17(26(3)4)19(29)16(22(24)32)21(31)23(11,33)20(30)14(9)18(15)28/h5-6,9,11,17,27,29-30,33H,7-8H2,1-4H3,(H2,24,32)/t9-,11-,17-,23-/m0/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(4S,4aS,5aR,12aS)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide</div></td></tr><tr><th>SMILES</th><td><div class="wrap">[H][C@@]12CC3=C(C(O)=CC=C3N(C)C)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Benzenoids</td></tr><tr><th>Class</th><td>Acenes and Derivatives</td></tr><tr><th>Subclass</th><td>Naphthacenes</td></tr><tr><th>Direct parent</th><td>Naphthacenes</td></tr><tr><th>Alternative parents</th><td>Anthracenecarboxylic Acids and Derivatives; Anthraquinones; Tetralins; Aminophenols; Tertiary Alcohols; Tertiary Amines; Primary Carboxylic Acid Amides; Polyols; Ketones; Carboxylic Acids; Enols; Polyamines; Enolates</td></tr><tr><th>Substituents</th><td>anthraquinone; tetralin; aminophenol; phenol derivative; benzene; tertiary alcohol; primary carboxylic acid amide; carboxamide group; tertiary amine; polyol; ketone; enolate; carboxylic acid derivative; polyamine; enol; carboxylic acid; amine; carbonyl group; alcohol; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the naphthacenes. These are compounds containing a naphthacene moiety, which is a polyaromatic hydrocarbon made of four linearly fused benzene rings.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of infections caused by susceptible strains of microorganisms, such as Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsial pox and tick fevers caused by Rickettsiae, upper respiratory tract infections caused by <i>Streptococcus pneumoniae</i> and for the treatment of asymptomatic carriers of <i>Neisseria meningitidis</i>.</td></tr><tr><th>Pharmacodynamics</th><td>Minocycline, the most lipid soluble and most active tetracycline antibiotic, is, like doxycycline, a long-acting tetracycline. Minocycline's effects are related to the inhibition of protein synthesis. Although minocycline's broader spectrum of activity, compared to other members of the group, includes activity against <i>Neisseria meningitidis</i>, its use as a prophylaxis is no longer recomended because of side effects (dizziness and vertigo). Current research is examining the possible neuroprotective effects of minocycline against progression of Huntington's Disease, an inherited neurodegenerative disorder. The neuroprotective action of minocycline may include its inhibitory effect on 5-lipoxygenase, an inflammatory enzyme associated with brain aging.</td></tr><tr><th>Mechanism of action</th><td>Minocycline passes directly through the lipid bilayer or passively diffuses through porin channels in the bacterial membrane. Tetracyclines like minocycline bind to the 30S ribosomal subunit, preventing the binding of tRNA to the mRNA-ribosome complex and interfering with protein synthesis.</td></tr><tr><th>Absorption</th><td>Rapidly absorbed from the gastrointestinal tract and absorption is not significantly impaired by ingestion of food or milk. Oral bioavailability is 100%.</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>55% to 76%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic.</p></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td>11-22 hours</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Minocycline has been observed to cause a dark discoloration of the thyroid in experimental animals (rats, minipigs, dogs and monkeys). In the rat, chronic treatment with minocycline has resulted in goiter accompanied by elevated radioactive iodine uptake and evidence of thyroid tumor production. Minocycline has also been found to produce thyroid hyperplasia in rats and dogs. LD<sub>50</sub>=2380 mg/kg (rat, oral), LD<sub>50</sub>=3600 mg/kg (mouse, oral)</td></tr><tr><th>Affected organisms</th><td><ul><li>Enteric bacteria and other eubacteria</li></ul></td></tr><tr><th>Pathways</th><td class="data-table-container"><table class="table table-condensed table-striped" id="pathways"><thead><tr><th>Pathway</th><th>Category</th></tr></thead><tbody><tr><td>Minocycline Action Pathway</td><td>Drug action</td></tr></tbody></table></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.7469</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              -
        </td>
        <td>0.9783</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.5711</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.7366</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.7968</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.7036</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9536</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8145</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9036</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.6805</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9088</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9071</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9232</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9081</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9058</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.7561</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.8909
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9091
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            1.0
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.4354 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9954
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.6783
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Medicis pharmaceutical corp</li>
<li>Triax pharmaceuticals llc</li>
<li>Aurobindo pharma ltd</li>
<li>Impax laboratories inc</li>
<li>Ranbaxy laboratories ltd</li>
<li>Teva pharmaceuticals usa inc</li>
<li>Watson laboratories inc</li>
<li>Lederle laboratories div american cyanamid co</li>
<li>Orapharma inc</li>
<li>Barr laboratories inc</li>
<li>Matrix laboratories ltd</li>
<li>Sandoz inc</li>
<li>Dr reddys laboratories ltd</li>
<li>Medicis Pharmaceutical Corporation</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.aaipharma.com">AAIPharma Inc.</a></li>
<li><a href="http://www.actavis.com">Actavis Group</a></li>
<li><a href="http://www.amerisourcebergen.com">Amerisource Health Services Corp.</a></li>
<li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li><a href="http://www.aurobindo.com">Aurobindo Pharma Ltd.</a></li>
<li>Barr Pharmaceuticals</li>
<li><a href="http://bryantranchprepack.com">Bryant Ranch Prepack</a></li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li><a href="http://www.dhscorp.com">Diversified Healthcare Services Inc.</a></li>
<li><a href="http://www.drreddys.com">Doctor Reddys Laboratories Ltd.</a></li>
<li><a href="http://www.globalphar.com">Global Pharmaceuticals</a></li>
<li><a href="http://www.impaxlabs.com">Impax Laboratories Inc.</a></li>
<li><a href="http://www.jnjcanada.com">Johnson &amp; Johnson Healthcare</a></li>
<li>Kaiser Foundation Hospital</li>
<li>Lake Erie Medical and Surgical Supply</li>
<li><a href="http://www.majorpharmaceuticals.com">Major Pharmaceuticals</a></li>
<li><a href="http://www.mckesson.com">Mckesson Corp.</a></li>
<li><a href="http://www.medicis.com">Medicis Pharmaceutical Co.</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.mylan.com">Mylan</a></li>
<li><a href="http://www.nucarerx.com">Nucare Pharmaceuticals Inc.</a></li>
<li><a href="http://www.ohmlabs.com">Ohm Laboratories Inc.</a></li>
<li><a href="http://www.orapharma.com">OraPharma</a></li>
<li><a href="http://www.parpharm.com">Par Pharmaceuticals</a></li>
<li><a href="http://www.patheon.com">Patheon Inc.</a></li>
<li>PCA LLC</li>
<li><a href="http://www.pdrx.com">PD-Rx Pharmaceuticals Inc.</a></li>
<li>Pharmaceutical Utilization Management Program VA Inc.</li>
<li><a href="http://www.pharmedixrx.com">Pharmedix</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.preferredpharmaceuticals.com">Preferred Pharmaceuticals Inc.</a></li>
<li>Prepackage Specialists</li>
<li>Professional Co.</li>
<li><a href="http://www.ranbaxy.com">Ranbaxy Laboratories</a></li>
<li><a href="http://www.rebelrx.com">Rebel Distributors Corp.</a></li>
<li>Resource Optimization and Innovation LLC</li>
<li><a href="http://www.sandhillspackaging.com">Sandhills Packaging Inc.</a></li>
<li><a href="http://www.sandoz.ca">Sandoz</a></li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li>
<li><a href="http://www.triaxpharma.com">Triax Pharmaceuticals LLC</a></li>
<li><a href="http://www.urlpharma.com">United Research Laboratories Inc.</a></li>
<li><a href="http://www.usvindia.com">USV Ltd.</a></li>
<li><a href="http://www.watson.com">Watson Pharmaceuticals</a></li>
<li><a href="http://www.wellspringpharm.com">Wellspring Pharmaceutical</a></li>
<li><a href="http://www.wyeth.com">Wyeth Pharmaceuticals</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Capsule</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01418">Acenocoumarol</a></td><td>The tetracycline, minocycline, may increase the anticoagulant effect of acenocoumarol.</td></tr><tr><td><a href="/drugs/DB00459">Acitretin</a></td><td>Increased risk of intracranial hypertension.</td></tr><tr><td><a href="/drugs/DB01370">Aluminium</a></td><td>Formation of non-absorbable complexes</td></tr><tr><td><a href="/drugs/DB01060">Amoxicillin</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00415">Ampicillin</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB01125">Anisindione</a></td><td>The tetracycline, minocycline, may increase the anticoagulant effect of anisindione.</td></tr><tr><td><a href="/drugs/DB01574">Attapulgite</a></td><td>Formation of non-absorbable complexes</td></tr><tr><td><a href="/drugs/DB01061">Azlocillin</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00355">Aztreonam</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB01602">Bacampicillin</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB01053">Benzylpenicillin</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00307">Bexarotene</a></td><td>Tetracycline derivatives like minocycline may enhance the adverse/toxic effect of Retinoic Acid Derivatives. Due to the risk of developing pseudotumor cerebri (also known as intracranial hypertension), avoid this combination of drugs if possible. If used concomitantly, monitor for evidence of this interaction (eg, dizziness, diplopia, headache).  </td></tr><tr><td><a href="/drugs/DB01294">Bismuth Subsalicylate</a></td><td>Formation of non-absorbable complexes</td></tr><tr><td><a href="/drugs/DB01373">Calcium</a></td><td>Formation of non-absorbable complexes</td></tr><tr><td><a href="/drugs/DB00258">Calcium Acetate</a></td><td>Calcium salts such as calcium acetate may decrease the serum concentration of tetracycline derivatives such as minocycline. In general, the coadministration of oral calcium salts and oral tetracycline derivatives should be avoided. Interactions may be able to be minimized by administering oral calcium preparations several hours before or after the dose of the oral tetracycline derivatives. Even with dose separation, therapy may still be compromised. Monitor for decreased therapeutic effect of oral tetracycline derivatives. </td></tr><tr><td><a href="/drugs/DB01164">Calcium Chloride</a></td><td>Calcium salts such as calcium chloride may decrease the serum concentration of tetracycline derivatives such as minocycline. In general, the coadministration of oral calcium salts and oral tetracycline derivatives should be avoided. Interactions may be able to be minimized by administering oral calcium preparations several hours before or after the dose of the oral tetracycline derivatives. Even with dose separation, therapy may still be compromised. Monitor for decreased therapeutic effect of oral tetracycline derivatives. </td></tr><tr><td><a href="/drugs/DB00578">Carbenicillin</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00766">Clavulanate</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB01147">Cloxacillin</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00930">Colesevelam</a></td><td>Bile acid sequestrants such as colesevelam may decrease the absorption of Tetracycline Derivatives. Monitor for decreased therapeutic effects of tetracycline derivatives if coadministered with a bile acid sequestrant. If these agents are used concomitantly, separate doses 2 or more hours to minimize the interaction. The manufacturer of colesevelam suggests that drugs should be administered at least 1 hour before or 4 hours after colesevelam.</td></tr><tr><td><a href="/drugs/DB01000">Cyclacillin</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00485">Dicloxacillin</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00266">Dicoumarol</a></td><td>The tetracycline, minocycline, may increase the anticoagulant effect of dicumarol.</td></tr><tr><td><a href="/drugs/DB00977">Ethinyl Estradiol</a></td><td>This anti-infectious agent could decrease the effect of the oral contraceptive</td></tr><tr><td><a href="/drugs/DB00926">Etretinate</a></td><td>Increased risk of intracranial hypertension</td></tr><tr><td><a href="/drugs/DB00301">Flucloxacillin</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00739">Hetacillin</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB01592">Iron</a></td><td>Formation of non-absorbable complexes</td></tr><tr><td><a href="/drugs/DB00893">Iron Dextran</a></td><td>Formation of non-absorbable complexes</td></tr><tr><td><a href="/drugs/DB00982">Isotretinoin</a></td><td>Increased risk of intracranial hypertension</td></tr><tr><td><a href="/drugs/DB01378">Magnesium</a></td><td>Formation of non-absorbable complexes</td></tr><tr><td><a href="/drugs/DB01377">Magnesium oxide</a></td><td>Formation of non-absorbable complexes</td></tr><tr><td><a href="/drugs/DB01397">Magnesium salicylate</a></td><td>Formation of non-absorbable complexes</td></tr><tr><td><a href="/drugs/DB01357">Mestranol</a></td><td>This anti-infectious agent could decrease the effect of the oral contraceptive</td></tr><tr><td><a href="/drugs/DB02443">Methicillin Acyl-Serine</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB01028">Methoxyflurane</a></td><td>The tetracycline, minocycline, may increase the renal toxicity of methoxyflurane.</td></tr><tr><td><a href="/drugs/DB00948">Mezlocillin</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00607">Nafcillin</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00713">Oxacillin</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00417">Penicillin V</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00319">Piperacillin</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB01604">Pivampicillin</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB01605">Pivmecillinam</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB01606">Tazobactam</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB01607">Ticarcillin</a></td><td>Minocycline may reduce the effect of Ticarcillin by inhibiting bacterial growth. Ticarcillin exerts its effects on actively growing bacteria. To achieve synergism, Ticarcillin should be administered at least 2 hours prior to using Minocycline.</td></tr><tr><td><a href="/drugs/DB00755">Tretinoin</a></td><td>Minocycline may increase the adverse effects of oral Tretinoin. Increase risk of pseudotumour cerebri. Concurrent therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB01401">Trisalicylate-choline</a></td><td>Formation of non-absorbable complexes</td></tr><tr><td><a href="/drugs/DB00682">Warfarin</a></td><td>The tetracycline, minocycline, may increase the anticoagulant effect of warfarin.</td></tr><tr><td><a href="/drugs/DB01593">Zinc</a></td><td>Formation of non-absorbable complexes</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Calcium and iron needs increased with long term use.</li>
<li>Do not take Aluminum or magnesium antacids or supplements while on this medication.</li>
<li>Take with food.</li></ul></td></tr></tbody></table>